Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: August 11, 2006
- Previous Holding: 17,403,364 ADRs
- New Holding: 17,426,924 ADRs
- Average Price: $55.10
This change resulted from a movement in the fund. The Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding director and connected person interests.
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan as of August 11, 2006 (17,426,924).
- Confirm the average transaction price of $55.10 for the fund movement.
- Note that Directors Dr. J P Garnier and Dr. M M Slaoui have potential interests in the fund shares alongside other employees.
- Understand that this filing does not contain financial performance data for the period.